All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Profusa vies for potential G3 Vision Labs acquisition

Digital health specialist Profusa has inked an option agreement to acquire G3 Vision Labs and its subsidiaries, giving the company…
NICE greenlights first non-invasive endometriosis diagnostic tools

The UK’s National Institute for Health and Care Excellence (NICE) has recommended two non-invasive endometriosis diagnostic tests for use across…
Local artery blocking device cuts knee osteoarthritis pain by 57%, study reveals

NextBiomedical’s artery-blocking device, Nexsphere-F, has significantly improved outcomes in patients with knee osteoarthritis in a European clinical study – a…
HLTH Europe 2026: Healthcare implementation key amid European innovation rush

As healthcare players from Europe and further afield continue to produce potentially game-changing healthcare innovations, attendees at HLTH Europe 2026…
Clariyon’s AI tool boosts sepsis care compliance in hospital study

Clariyon’s artificial intelligence (AI)-powered sepsis care agent has shown potential in improving a physician’s ability to provide quality care to…

Advanced Medical Solutions mulls £715m HB Fuller takeover bid

Adhesives manufacturing giant, HB Fuller, has put £715m ($942.5m) on the table to acquire wound care specialist Advanced Medical Solutions…
BrightHeart secures CE mark for AI-powered prenatal ultrasound platform

Parisian medtech company, BrightHeart, has obtained a CE mark for its artificial intelligence (AI)-based tool to optimise the prenatal ultrasound…
Tissium wins €60m to bring sutureless nerve repair system to market

Following the US Food and Drug Administration’s (FDA) decision to award a De Novo authorisation to Tissium’s sutureless nerve repair…
PorTal Access secures FDA clearance for vascular access ports

The US Food and Drug Administration (FDA) has granted Miami-based medical device specialist, PorTal Access clearance for its range of…
HLTH Europe 2026: enriching the patient journey with health technologies

With the pharma, biotech and medtech sectors debuting new and potentially life-changing innovations for patients at a rapid pace, many…